These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34474911)

  • 1. Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report.
    Almalki B; Shroff H; Maddur H; Caicedo J; Kane C
    Transplant Proc; 2021 Oct; 53(8):2567-2569. PubMed ID: 34474911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 4. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
    Kuter DJ; Allen LF
    Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of avatrombopag for the treatment of thrombocytopenia.
    Virk ZM; Kuter DJ; Al-Samkari H
    Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
    [No Abstract]   [Full Text] [Related]  

  • 8. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
    Nomoto M; Ferry J; Hussein Z
    J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.
    Al-Samkari H
    Drugs Today (Barc); 2018 Nov; 54(11):647-655. PubMed ID: 30539164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
    Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
    Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avatrombopag for the treatment of immune thrombocytopenia.
    Długosz-Danecka M; Zdziarska J; Jurczak W
    Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
    Maitland HS
    Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avatrombopag: First Global Approval.
    Shirley M
    Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
    Gabrail N; Smith C
    Am J Case Rep; 2020 Nov; 21():e927008. PubMed ID: 33191394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease.
    Lozano ML
    Rev Esp Enferm Dig; 2021 Feb; 113(2):136-140. PubMed ID: 33233913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
    Nilles KM; Flamm SL
    Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.
    Nomoto M; Pastino G; Rege B; Aluri J; Ferry J; Han D
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):188-195. PubMed ID: 28339166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.
    Tran TB; Downing L; Elmes JB; Arnall JR; Moore DC
    J Pharm Pract; 2024 Feb; 37(1):184-189. PubMed ID: 36113085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.